You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

401 Results
Guidelines and Advice
Status: In-Review
ID: 17-1
Version: 2
Mar 2015
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
Exceptional Access Program
    fruquintinib - For the treatment of metastatic colorectal cancer according to specific criteria
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
High Cost Therapy Funding Program
    Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Mar 2026
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Status: Archived
ID: FA3
Dec 1969

Pages